# A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

> **NCT05298254** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 505 (actual)

## Conditions studied

- Herpes Simplex

## Interventions

- **BIOLOGICAL:** Non-adjuvanted HSV formulation 1
- **BIOLOGICAL:** Non-adjuvanted HSV formulation 2
- **BIOLOGICAL:** Non-adjuvanted HSV formulation 3
- **BIOLOGICAL:** HSV formulation 1 with adjuvant 1
- **BIOLOGICAL:** HSV formulation 2 with adjuvant 1
- **BIOLOGICAL:** HSV formulation 3 with adjuvant 1
- **BIOLOGICAL:** HSV formulation 1 with adjuvant 2
- **BIOLOGICAL:** HSV formulation 2 with adjuvant 2
- **BIOLOGICAL:** HSV formulation 3 with adjuvant 2
- **DRUG:** Placebo
- **BIOLOGICAL:** HSVTI_F1
- **BIOLOGICAL:** HSVTI_F2

## Key facts

- **NCT ID:** NCT05298254
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-07
- **Primary completion:** 2025-06-12
- **Final completion:** 2025-06-12
- **Target enrollment:** 505 (ACTUAL)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05298254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05298254, "A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05298254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*